Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation
Year: 2016
Type: article
Abstract: Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification (HO) in humans and causes skeletal deformities, movement impairment, and premature death. Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1(R206H) , that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO. We showed previously that the retinoic acid receptor γ (RARγ) agonist palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease. Here we report that the drug additionally prevents spontaneous HO, using a novel conditional-on knock-in mouse line carrying the human ACVR1(R206H) mutation for classic FOP. In addition, palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates when given to lactating mothers. Importantly, palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP. © 2016 American Society for Bone and Mineral Research.
DOI: 10.1002/jbmr.2820
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Yale University, University of Pennsylvania, International Fibrodysplasia Ossificans Progressiva Association, Weldon FOP Research Fund, National Institutes of Health, U.S. Army, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Penn Center for Musculoskeletal Disorders, U.S. Army Medical Research Acquisition Activity
Awards: G1461614003, G1627436685, The Cellular and Molecular Basis of FOP Lesions, G5850682332, Core Center for Musculoskeletal Disorders, G600526216, Regulation of Skeletal Growth by Nuclear Retinoid Receptors, G8389391685, Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application)
OpenAlex ID: W2278281289
